New nuclear medicine imaging method has potential for cancer imaging

A new nuclear medicine imaging method could help diagnose widespread tumours, such as breast, colon, pancreas, lung and head and neck cancer better than current methods, with less inconvenience to patients and with equal or improved accuracy, according to researchers from the University Hospital of Heidelberg and at the German Cancer Research Center. The paper, ‘A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts’, was published in Journal of Nuclear Medicine

Probiotics might not be effective for health in the human gut

New research suggests that probiotics might not be as effective as we think. Through a series of experiments looking inside the human gut, researchers found that many people's digestive tracts prevent standard probiotics from successfully colonising them. Furthermore, taking probiotics to counterbalance antibiotics could delay the return of normal gut bacteria and gut gene expression to their naïve state. The research publishes as two back-to-back papers in the journal Cell.

c-MYC protein contributes to the formation of adenomas in the colon

A new study carried out by a team led by Professor Heiko Hermeking at the Institute of Pathology at LMU (and German Cancer Consortium) shows that the regulatory protein c-MYC, which plays an important role in promoting the development of many types of tumours, induces the production of a transcription factor that increases the numbers of stem cells in the intestinal epithelium, and thereby contributes to the formation of adenomas in the colon.

Benign growths more heterogeneous than colorectal cancer tumours

Chromosomal catastrophes have been found to occur along the evolutionary timeline of colorectal cancer  development, according to new research led by Queen Mary University of London. The paper, 'The evolutionary landscape of colorectal tumorigenesis', published in Nature Ecology & Evolution, compared the genetics of benign and cancerous bowel tumours and revealed that the benign growths were more heterogeneous than the cancerous tumours.

Positive results for ABX464 as an oral treatment ulcerative colitis

Abivax has announced topline results from its Phase 2a clinical trial, ABX464-101, conducted in 32 patients for induction treatment of moderate-to-severe ulcerative colitis (UC), refractory to anti-TNF monoclonal antibodies or corticosteroids. In summary, the topline data indicate that ABX464 was safe, well-tolerated, and demonstrated statistically significant efficacy based on both clinical and endoscopic endpoints in this study.

Pre-emptive analgesia may cut post-op pain in anorectal surgery

Preemptive pain medication is safe and reduces pain in the early postoperative period for patients undergoing anorectal surgery (ARS), according to a study published in the journal of Diseases of the Colon & Rectum. The researchers found that patients in the active group had significantly less pain in the post-anaesthesia care unit and at eight hours postoperatively. Furthermore, significantly fewer participants in the active group used narcotics in the post-anaesthesia care unit and at eight hours postoperatively.